Payment overview · 2025
General Payments
$1,603.62
85 reported records · 23 companies
Healthcare provider profile · identity verified
Thomas William Miller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NOBLESVILLE, IN · NPI 1386725638
Verified facts
What the public records show
CMS Open Payments records show Thomas William Miller, M.D. received $1,603.62 in general payments during 2025 across 85 reported records.
ABBVIE INC. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.79 | 13.1% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.60 | 10.2% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.28 | 9.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.15 | 8.0% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.13 | 6.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.43 | 6.8% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $79.98 | 5.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.71 | 4.8% | 4 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $73.26 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $64.68 | 4.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.41 | 4.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.12 | 3.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.70 | 3.4% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $51.49 | 3.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.31 | 3.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.28 | 2.5% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.48 | 1.5% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.06 | 1.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.41 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 1.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.91 | 1.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $14.89 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.60 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,603.62 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.28 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.09 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $110.13 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.55 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $102.24 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $95.96 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.05 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.05 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.43 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.40 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $79.98 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.15 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $73.26 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $73.26 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.41 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $58.12 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.31 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.31 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.69 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 132 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
132 | 132 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 108 |
| Losartan Potassium | Losartan Potassium | 373 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 307 | 160 |
| Tramadol Hcl | Tramadol Hcl | 303 | 47 |
| Lorazepam | Lorazepam | 286 | 50 |
| Cephalexin | Cephalexin | 277 | 159 |
| Lisinopril | Lisinopril | 247 | 69 |
| Alprazolam | Alprazolam | 219 | 38 |
| Furosemide | Furosemide | 207 | 61 |
| Allopurinol | Allopurinol | 203 | 54 |
| Glimepiride | Glimepiride | 185 | 50 |
| Omeprazole | Omeprazole | 184 | 49 |
| Gabapentin | Gabapentin | 178 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 43 |
| Metformin Hcl | Metformin Hcl | 147 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 139 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 41 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 132 | 132 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 34 |
| Spironolactone | Spironolactone | 119 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 30 |
| Potassium Chloride | Potassium Chloride | 105 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 30 |
| Januvia | Sitagliptin Phosphate | 101 | 24 |
| Sertraline Hcl | Sertraline Hcl | 98 | 32 |
| Simvastatin | Simvastatin | 98 | 28 |
| Clonazepam | Clonazepam | 96 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 96 | 19 |
| Eliquis | Apixaban | 92 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 25 |
| Prednisone | Prednisone | 89 | 50 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 57 |
| Ozempic | Semaglutide | 86 | 18 |
| Carvedilol | Carvedilol | 84 | 26 |
| Ondansetron Odt | Ondansetron | 83 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 18 |
| Metformin Hcl Er | Metformin Hcl | 76 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 76 | 19 |
| Fluconazole | Fluconazole | 75 | 35 |
| Montelukast Sodium | Montelukast Sodium | 74 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 20 |
| Meloxicam | Meloxicam | 71 | 21 |
| Meclizine Hcl | Meclizine Hcl | 70 | 31 |
| Carisoprodol | Carisoprodol | 58 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 14 |
| Diazepam | Diazepam | 53 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Methylprednisolone | Methylprednisolone | 50 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Clonidine Hcl | Clonidine Hcl | 45 | 16 |
| Finasteride | Finasteride | 43 | 13 |
| Jardiance | Empagliflozin | 43 | 12 |
| Nystatin | Nystatin | 42 | 20 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Glyburide | Glyburide | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Mupirocin | Mupirocin | 38 | 28 |
| Nitroglycerin | Nitroglycerin | 38 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 21 |
| Torsemide | Torsemide | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 28 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | 16 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Valsartan | Valsartan | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Temazepam | Temazepam | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,603.62 · 85 records | ABBVIE INC. | AIRSUPRA, AREXVY, ARISTADA, Auvelity, Azstarys, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, ETERNA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, LYBALVI, Leqembi, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYWAV, ZEPBOUND, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error